HHS IG considers service of monetary value to be remuneration, IG branch chief McAnaney warns.
Executive Summary
HHS IG CONSIDERS SERVICE OF MONETARY VALUE AS REMUNERATION, OIG Industry Guidance Branch Chief Kevin McAnaney warned at the May 20 Food and Drug Law Institute conference in Washington, D.C. The OIG considers any gift of service from a manufacturer a prosecutable action "regardless of what the services are. If they have monetary value, then they are classified as remuneration," McAnaney said. "If a supplier or manufacturer is basically providing that service to them, at no cost to them, we think that is double-dipping, and that is basically a discount."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth